

## Jim Briggs

Associate, New York  
212.554.1348  
Jim.Briggs@blbglaw.com



---

**Jim Briggs** is an associate at BLB&G, where he focuses on securities litigation on behalf of the firm's institutional investor clients. He practices out of the firm's New York office.

Jim has contributed to numerous matters at BLB&G, including litigation involving Willis Towers Watson, Tile Shop Holdings, Equifax, Adeptus Health, HeartWare International, Wells Fargo & Company, comScore, Clovis Oncology, Salix Pharmaceuticals, JPMorgan Chase & Co., and Merck & Co. Most recently, he has been a member of the team litigating *Homyk v. ChemoCentryx, Inc. et al.*, a case against ChemoCentryx and its CEO alleging fraud related to the safety, efficacy, and application for FDA approval of ChemoCentryx's proprietary vasculitis drug, avacopan.

Beyond his litigation practice, Jim has authored articles in leading scientific journals, including *Conservation Genetics* and *Emerging Infectious Diseases*.

Prior to becoming an associate, Jim served as both a staff attorney and senior staff attorney at BLB&G.

Jim earned his J.D. from Fordham University School of Law and his B.S. from Cornell University in Biological Sciences, graduating *cum laude*.

### Education

- Fordham University School of Law, 2010, J.D.
- Cornell University, 2007, B.S., *cum laude*, Biological Science

### Admission

- New York